Plaintiff Firms Push Investor Alerts on Securities Suits as Filing Deadlines Near

Overview

• - A wave of investor notices this week promoted securities class actions across more than a dozen U.S.-listed companies with lead-plaintiff deadlines in April and May 2026.
• - Rosen Law Firm led the outreach, with Bernstein Liebhard and The Law Offices of Frank R. Cruz also issuing alerts that listed class periods and steps to seek lead status.
• - The complaints cite a range of alleged misstatements, including FDA and clinical issues (Aquestive’s Anaphylm human‑factors concerns and uniQure’s pivotal study approval and BLA timing), financing claims (Plug Power’s prospects for a DOE loan), and accounting or controls (Kyndryl’s financial reporting and internal controls).
• - Other suits flagged alleged sales and product claims (PayPal’s salesforce readiness and growth targets, REGENXBIO’s RGX‑111 efficacy and safety statements, Gartner’s contract‑value growth messaging), stock activity (PomDoctor’s promotion and insider selling), and misrepresented partnerships (Richtech’s stated Microsoft ties), with Zynex accused of revenue from an overbilling scheme.
• - The firms emphasized that no class is certified, investors can participate without upfront costs under contingency agreements, and lead plaintiffs can help direct counsel choice, discovery, and any settlement talks.